Smoleński R T, de Jong J W, Janssen M, Lachno D R, Zydowo M M, Tavenier M, Huizer T, Yacoub M H
Department of Biochemistry, Academic Medical School, Gdańsk, Poland.
J Mol Cell Cardiol. 1993 Jan;25(1):67-74. doi: 10.1006/jmcc.1993.1008.
In contrast to cardiac purine metabolism, little is known about pyrimidine catabolism in heart. We therefore investigated uridine and uracil formation in ischemic rat and human hearts. Human donor hearts accumulated uridine 3 x (P < 0.05) before implantation. Hearts released this pyrimidine during implantation or correction of cardiac defects. During the former systemic blood uridine rose 38% (P < 0.05). In explanted human hearts, uridine was the only pyrimidine released during reperfusion; isolated, perfused rat hearts produced initially 3 x more uracil than uridine. Uridine phosphorylase activity in human heart homogenate was 3.4 mU/g wet weight, i.e. 60 x lower than that in rat myocardium (198 mU/g, P < 0.02); its purine counterpart, nucleoside phosphorylase, differed much less in activity (0.32 and 1.12 U/g, respectively; P < 0.001). Thus human heart is virtually devoid of uridine phosphorylase, contrasting rat heart. Consequently uridine accumulates in ischemic human heart while uracil production predominates in rat heart.
与心脏嘌呤代谢不同,人们对心脏嘧啶分解代谢知之甚少。因此,我们研究了缺血大鼠心脏和人心脏中尿苷和尿嘧啶的生成情况。人类供体心脏在植入前积累了3倍的尿苷(P < 0.05)。心脏在植入或心脏缺陷矫正过程中释放出这种嘧啶。在前者过程中,全身血液中的尿苷升高了38%(P < 0.05)。在离体人心脏中,尿苷是再灌注过程中释放的唯一嘧啶;分离的灌注大鼠心脏最初产生的尿嘧啶比尿苷多3倍。人心脏匀浆中的尿苷磷酸化酶活性为3.4 mU/g湿重,即比大鼠心肌中的活性低60倍(198 mU/g,P < 0.02);其嘌呤对应物核苷磷酸化酶的活性差异则小得多(分别为0.32和1.12 U/g;P < 0.001)。因此,与人心脏形成对比的是,人心脏实际上几乎没有尿苷磷酸化酶。结果,尿苷在缺血人心脏中积累,而尿嘧啶的生成在大鼠心脏中占主导。